DiaMedica TherapeuticsDMAC +5.53%31 Buyback Yield % is 0.00 as of Jul. 02, 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 745 Biotechnology companies, DiaMedica Therapeutics ranks worse than 134228.05% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
DiaMedica Therapeutics Buyback Yield % Related Terms
DiaMedica Therapeutics Buyback Yield % Historical Data
* Premium members only.
The historical data trend for DiaMedica Therapeutics's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DMAC vs PRLD, RCKT, TENX: Buyback Yield % Comparison
For the Biotechnology subindustry, DiaMedica Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DiaMedica Therapeutics Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DiaMedica Therapeutics's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where DiaMedica Therapeutics's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DiaMedica Therapeutics (DMAC) has a Buyback Yield % of 0.00 as of Jul. 02, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on DiaMedica Therapeutics and its competitors. According to the industry distribution chart, DiaMedica Therapeutics ranks #999999 out of 745 companies in the Biotechnology industry.
Is DiaMedica Therapeutics' Buyback Yield % too high?
DiaMedica Therapeutics' current Buyback Yield % is 0.00. Based on the distribution chart, DiaMedica Therapeutics ranks #999999 out of 745 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Buyback Yield % compare to PRLD and RCKT?
According to the Biotechnology industry distribution chart, DiaMedica Therapeutics ranks #999999 out of 745 companies for Buyback Yield %. This places DiaMedica Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Buyback Yield % is 0.00 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score
Get the complete analysis for DMAC
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMAC has been successfully added to your 
